Targeting of the AKT/m-TOR Pathway: Biomarkers of Resistance to Cancer Therapy--
AKT/m-TOR Pathway and Resistance to Cancer Therapy.
10.3779/j.issn.1009-3419.2018.01.09
- Author:
Liudmila V SPIRINA
1
;
Irina V KONDAKOVA
1
;
Natalia V TARASENKO
2
;
Elena M SLONIMSKAYA
3
;
Evgeny A USYNIN
3
;
Alexey K GORBUNOV
3
;
Zahar A YURMAZOV
3
;
Svetlana Yu CHIGEVSKAYA
3
Author Information
1. Laboratory of Tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Russia.
2. Department of Medical Genetics, Siberian State Medical University, Tomsk, Russia.
3. Surgical Department, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Russia.
- Publication Type:Journal Article
- Keywords:
AKT/m-TOR signaling pathway;
Molecular markers;
Resistance to cancer therapy
- MeSH:
Animals;
Biomarkers, Tumor;
metabolism;
Drug Resistance, Neoplasm;
Humans;
Molecular Targeted Therapy;
methods;
Neoplasms;
drug therapy;
metabolism;
pathology;
Proto-Oncogene Proteins c-akt;
metabolism;
Signal Transduction;
drug effects;
TOR Serine-Threonine Kinases;
metabolism
- From:
Chinese Journal of Lung Cancer
2018;21(1):63-66
- CountryChina
- Language:English
-
Abstract:
Resistance to cancer therapy continues to be a major limitation for the successful treatment of cancer. There are many published studies on therapy resistance in breast and prostate cancers; however, there are currently no data on molecular markers associated with resistance. The conflicting data were reported regarding the AKT/m-TOR signaling pathway components as markers predicting resistance. The AKT/m-TOR signaling pathway is involved in the development of many human cancers; its activation is related to cell proliferation, angiogenesis, apoptosis, as well as to therapy resistance. Molecular alterations in the AKT/m-TOR signaling pathway provide a platform to identify universal markers associated with the development of resistance to cancer therapy.
